Publication: 2834

Publication: 2834

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Eur J Cancer vol 94 115-25

Year:: 2018
Type:: Manuscript
Funding:: NCTN
Endpoint:: Secondary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: ppub

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: Yes
Book Volume:: 7

Parents:: 2721 2830
Children:: None

Program:: OGC
Primary Committee:: GU
Sec. Committees:

Pharmas:: Exelixis, Inc
Grants:: U10CA180821, U10CA180882, U10CA180791, U10CA180833, U10CA180850, U10CA180857, U10CA180867, P30 CA008748, U24176171

Corr. Author:
Authors:: Toni K. Choueiri Colin Hessel Susan Halabi Ben Sanford M. Dror Michaelson Olwen Hahn Meghara Walsh Thomas Olencki Joel Picus Eric J. Small Shaker Dakhil Darren R. Feldman Milan Mangeshkar Christian Scheffold Daniel George Michael J. Morris

Networks:: CA824, KS055, LAPS-IL057, LAPS-MA036, LAPS-MO011, LAPS-NC010, LAPS-NY016, LAPS-OH007

Study: Alliance-A031203
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords: